Promotion and new appointment at Lipoxen
This article was originally published in Scrip
Executive Summary
The UK biopharmaceutical company Lipoxen has promoted Dr Peter Laing from director of business development to chief operating officer, and appointed Dr Ajay Agrawal head of business development. Dr Laing joined Lipoxen in March 2002 and has played a leading role in developing the company's R&D and business development operations. Dr Agrawal has extensive experience in the biotech and pharma industry and was a founder of the drug delivery company polyMASC Pharmaceuticals.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.